Evropská unie - čeština - EMA (European Medicines Agency)

ferring pharmaceuticals a/s - degarelix - prostatetické novotvary - endokrinní terapie - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

sun pharmaceutical industries europe b.v., hoofddorp array - 22574 ganirelix-acetÁt - injekční roztok v předplněné injekční stříkačce - 0,25mg/0,5ml - ganirelix